Last reviewed · How we verify
LNG
LNG (levonorgestrel) is a synthetic progestin that prevents pregnancy by suppressing ovulation and altering cervical mucus and endometrial conditions.
LNG (levonorgestrel) is a synthetic progestin that prevents pregnancy by suppressing ovulation and altering cervical mucus and endometrial conditions. Used for Oral contraception, Emergency contraception (Plan B), Intrauterine contraceptive device.
At a glance
| Generic name | LNG |
|---|---|
| Also known as | Levonorgestrel implant |
| Sponsor | FHI 360 |
| Drug class | Progestin (synthetic) |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception |
| Phase | FDA-approved |
Mechanism of action
Levonorgestrel works primarily by inhibiting the LH surge necessary for ovulation. It also increases cervical mucus viscosity to impede sperm transport and alters the endometrium to reduce implantation likelihood. As a marketed contraceptive, it is available in multiple formulations including oral pills, emergency contraception, and intrauterine devices.
Approved indications
- Oral contraception
- Emergency contraception (Plan B)
- Intrauterine contraceptive device
Common side effects
- Nausea
- Headache
- Dizziness
- Breast tenderness
- Irregular bleeding
Key clinical trials
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia (PHASE2)
- Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia (PHASE2, PHASE3)
- Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel (PHASE3)
- Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
- A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants (PHASE1)
- Uterine Preservation Via Lifestyle Transformation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LNG CI brief — competitive landscape report
- LNG updates RSS · CI watch RSS
- FHI 360 portfolio CI